Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study - The Lancet Oncology
Biomarkers in Targeted Therapy for Colorectal Cancer
![PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2e5f89dec8a25afc1d61dc3d7197afa33839845d/3-Figure2-1.png "PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar")
PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar
Biomarkers in colorectal cancer: Current clinical utility and future perspectives
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
EGFR signaling in colorectal cancer: a clinical perspective | GICTT
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer | Oncogene
EGFR | Cancer Genetics Web
Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway - ScienceDirect
Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies | Personalized Medicine
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. - Abstract - Europe PMC
APMG Colon Molecular Pathways
Epidermal growth factor receptor (EGFR)-related signaling pathway in... | Download Scientific Diagram
Precision medicine for metastatic colorectal cancer in clinical practice - Julian E. Riedesser, Matthias P. Ebert, Johannes Betge, 2022
Clinical management of metastatic colorectal cancer in the era of precision medicine - Ciardiello - 2022 - CA: A Cancer Journal for Clinicians - Wiley Online Library
Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution - ScienceDirect
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer | Pharmacogenomics
Over-expression of EGFR regulated by RARA contributes to 5-FU resistance in colon cancer | Aging
RESISTANCE TO ANTI-EGFR THERAPIES IN COLORECTAL CANCER – Sanguine Bio Researcher Blog
Colorectal adenocarcinoma‐derived EGFR mutants are oncogenic and sensitive to EGFR‐targeted monoclonal antibodies, cetuximab and panitumumab - Kim - 2020 - International Journal of Cancer - Wiley Online Library
EGFR signaling in colorectal cancer: a clinical perspective | GICTT
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies | Journal of Molecular Medicine
New combination therapy offers bowel cancer patients extra treatment option
Cancers | Free Full-Text | Immune Resistance and EGFR Antagonists in Colorectal Cancer
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies | Journal of Molecular Medicine
Frontiers | Targeting EGFR in Esophagogastric Cancer
Polarization of macrophages in the tumor microenvironment is influenced by EGFR signaling within colon cancer cells | Oncotarget
Y‑box‑binding protein 1 inhibits apoptosis and upregulates EGFR in colon cancer
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
